Cozentyx works by blocking interleukin-17 (IL-17), a signalling protein (cytokine) that regulates the immune system and is related to the body's inflammatory response.
Cosentyx is available as a subcutaneous (under the skin) injection.
The manufacturer of Cosentyx offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Drug Identification Number (DIN): 02438070, 02438062